ReviewJournal of translational medicine2023
Alpha-melanocyte stimulating hormone (α-MSH): biology, clinical relevance and implication in melanoma.
Review in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Associations between month/season of birth and health outcomes: an umbrella review of systematic reviews and meta-analyses.Journal of global health · 2026Pooled it
- Neural-tumor interactions: bidirectional regulatory mechanisms and nervous system-targeted tumor therapeutic strategies.Biomarker research · 2026Review
- Phytochemical Composition and In Vitro Anti-Pigmentation Activity ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Bioactive Lipid Mediator Resolvin D5 Suppresses Melanogenesis in α-MSH-Stimulated B16F10 Cells via ROS-Associated p38/β-Catenin/MITF Regulation.Journal of microbiology and biotechnology · 2026Article
- Article
- Targeting Peptidergic Systems for Melanoma Treatment.Cancers · 2026Review
- Skin-Lightening Efficacy of Leatherleaf Fern Extract and a Leatherleaf Fern-Based Facial Serum In Vitro and Clinical Trial.Journal of cosmetic dermatology · 2026Article
- Single-cell mapping of tumor-driven macrophage reprogramming via ETV4-MC1R underlies immunotherapy resistance in colorectal cancer.International journal of surgery (London, England) · 2026Article
- Quercetin and Its Nano-Based Formulations Against Skin Cancer: A Narrative Review.Health science reports · 2026Article
- Herbal medicine for melanin regulation: biological synthesis, effective formulas/compounds, and biopharmaceutical methods.Journal of natural medicines · 2026Review
- NDP-MSH rescues LPS-induced neuroinflammation, synaptic deficits, and depressive-like behaviors in mice: involvement of MC1R-cAMP/PKA signaling.Frontiers in pharmacology · 2026Article
- Emerging perspectives on the selective autophagy of melanosomes: melanophagy.Experimental & molecular medicine · 2025Review
- Formulation and evaluation of ulvan-functionalized cumin oil nanoemulsions for antioxidant, anti-photoaging, and anti-melanogenesis activities in skin cells.Bioresources and bioprocessing · 2025Article
- Review
- Neuroendocrinology and the Genetics of Obesity.Endocrinology · 2025Review
- Deciphering melanophagy: role of the PTK2-ITCH-MLANA-OPTN cascade on melanophagy in melanocytes.Autophagy · 2025Article
- Do Melanocytes Have a Role in Controlling Epidermal Bacterial Colonisation and the Skin Microbiome?Experimental dermatology · 2025Article
- Antimicrobial Neuropeptides and Their Receptors: Immunoregulator and Therapeutic Targets for Immune Disorders.Molecules (Basel, Switzerland) · 2025Review
- Article
- Dual Role of α-MSH in Colitis Progression: Mediating Neutrophil Differentiation via Bone Marrow.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha-melanocyte stimulating hormone (α-MSH) and its receptor, melanocortin 1 receptor (MC1R), have been proposed as potential target for anti-cancer strategies in melanoma research, due to their tissue specific expression and involvement in melanocyte homeostasis. However, their role in prevention and treatment of melanoma is still debated and controversial. Although a large body of evidence supports α-MSH in preventing melanoma development, some preclinical findings suggest that the α-MSH downstream signalling may promote immune escape and cancer resistance to therapy. Additionally, in metastatic melanoma both MC1R and α-MSH have been reported to be overexpressed at levels much higher than normal cells. Furthermore, targeted therapy (e.g. BRAF inhibition in BRAF
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.